Hester Biosciences Limited (NSE: HESTERBIO) has recommended a final dividend of ₹11 per equity share for the financial year ended March 31, 2026, its board decided at a meeting on May 15, 2026. The announcement was accompanied by the submission of financial results for the quarter ended June 30, 2026, filed with NSE on July 30, 2026. The ₹11 payout represents a 57.1% increase over the ₹7 per share dividend declared for FY25, and is the highest final dividend the company has declared since FY22.

Dividend Details

The dividend is subject to approval by shareholders at the ensuing Annual General Meeting. The record date for dividend eligibility has not been separately announced in the current filing.

Dividend History and Trend Analysis

A review of Hester Biosciences' dividend track record over the past seven years reveals a notable fluctuation in payout levels. The company paid ₹7.00 in FY19, followed by ₹6.60 in FY20, before rising to ₹10.00 in both FY21 and FY22. The payout then declined to ₹8.00 in FY23 and further to ₹6.00 in FY24, before recovering to ₹7.00 in FY25. The FY26 declaration of ₹11.00 breaks above the previous peak of ₹10.00 set in FY21 and FY22, suggesting a meaningful improvement in the company's distributable surplus and board confidence in earnings sustainability.

Market Context

Since live quote and trade data were not available at the time of this report, a precise dividend yield calculation requires investors to reference the current market price of HESTERBIO on NSE. As a reference point, investors can calculate yield as: Dividend Yield = (₹11.00 / Current Market Price) x 100. The stock's 52-week range and prevailing price relative to that range would further contextualize whether the current yield represents an above-average income opportunity within the veterinary pharmaceuticals and biologicals segment. Investors are advised to verify the latest traded price on NSE before computing yield.

Company Background

Hester Biosciences Limited is an Ahmedabad-based animal health company engaged in the manufacture of veterinary vaccines and health products. The company operates in a specialized niche within the broader Indian pharmaceuticals space, serving both domestic and export markets across poultry and livestock segments. Its consistent dividend payment history spanning at least seven consecutive financial years reflects an uninterrupted commitment to shareholder returns, even through periods of earnings variability.

What This Means for Investors

The record ₹11 per share payout signals that Hester Biosciences' board views FY26 earnings as materially stronger than FY24 and FY25. Investors tracking dividend growth as an earnings quality indicator will note that the two-year recovery from ₹6.00 in FY24 to ₹11.00 in FY26 represents an 83.3% cumulative increase in per-share dividend over two years. The Q1 FY27 financial results filed simultaneously on July 30, 2026, provide an additional data point for assessing whether earnings momentum underpinning the higher payout has carried into the current fiscal year. Investors should review the full financial results filing on the NSE platform for revenue, EBITDA, and net profit figures before drawing conclusions on valuation and payout sustainability.